KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations severely limit therapeutic options. The results of a study led by the Center for Cancer Research at the Medical University of Vienna, recently published in the journal EMBO Molecular Medicine, now raise a previously little-considered strategy: the targeted blockade of the EGFR signaling pathway – even in the presence of a KRAS mutation. This could make KRAS-mutated colon cancer more treatable than previously thought.

A case in which a sperm donor was later found to be carrying a cancer-causing pathogenic variant in his gametes has highlighted the lack of cross-border regulation in Europe, which can result in the multiple use of gametes in  families and risks inbreeding and the abnormal  dissemination of inherited diseases.

Lead author Camilo Faust Akl and senior author Francisco Quintana, PhD, both of the Ann Romney Center of Neurologic Diseases at Brigham and Women’s Hospital, published a paper in Nature, “Glioblastoma-instructed astrocytes suppress tumor-1 specific T-cell immunity

The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale).

Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an additional challenge in everyday clinical practice. A therapy using the active ingredient rivaroxaban specifically tailored to children was successfully tested for the first time in 2020. Now, long-term data confirm the benefits of this drug treatment even for extended use. The study was conducted by an international research team led by MedUni Vienna and has been published in the journal The Lancet Haematology.